SAN FRANCISCO, CA, Mar 30, 2020 – (ACN Newswire) – Award-winning global digital patient recruitment Platform GeoMap Clinical said it was making video visits (telemedicine, telehealth), instantly available to patients…
Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs…
Hong Kong listed VPower Group International Holdings Limited (VPower Group), a leading DPG station owner and operator in Asia, announced that the Group has entered into a distribution agreement with…
Net Profit Surged by Over 75%; with Financial Technology Boosting Business Transformation GF Securities Co., Ltd. (“GF Securities” or the “Company”, together with its subsidiaries, the “Group”; HKSE: 1776; SZSE:…
Toll Income up 27.4% to approximately RMB1,255 million with RMB0.12 of Final Dividend Shows a Prominent Sustainable Development Chengdu Expressway Co., Ltd. (“Chengdu Expressway” or the “Company”, together with its…
Completes Acquisition Of Vastec; Further Expands Product Portfolio, Distribution Network And Hospital Coverage IVD Medical Holding Limited (“IVD Medical” or the “Group”), a leading distributor of In Vitro Diagnostic (“IVD”)…
Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries collectively the “Group”) (stock code: 1977), a leading electrical and mechanical (“E&M”) engineering service provider in Hong Kong with…
Profit Soars in Four Major Segments, with Double Profit in Institutional Services and Trading Segment Shenwan Hongyuan Group Co., Ltd. (hereinafter referred to as “Shenwan Hongyuan” or the “Company”; stock…
Steadily Develops Tin Mining and Excavation Business; Abundant Resources and Reserves Bolsters Production Expansion Greentech Technology International Limited (“Greentech Technology” or the “Company”, together with its subsidiaries the “Group”; stock…
The Morningstar International Fund Awards are set to recognize the China 2020 winners on March 26. The China Southern Selected Growth Balanced Fund (202023) from China Southern Asset Management Co.,…
Key Enterprises Saw Steady Growth, Backflow of Resources Emphasized According to South China Morning Post, Legend Holdings Corporation (3396.HK) announced annual results of the Company and its subsidiaries for the…
On February 3, 2020, West Capital International (WCI) obtained authorised supervision from Financial Transactions and Reports Analysis Centre of Canada (FINTRAC) with immediate effect, meaning WCI officially entered the Canadian…
Revenue up 4% Year-on-Year to HK$3,252.3 Million With Adjusted Net Profit at HK$135.0 Million; To Launch Six New Canned Food Products and Enhance Delivery Service to Mitigate Current Headwinds and…
Revenue increased significantly of 34.0% Y-O-Y Haitong UniTrust International Leasing Co., Ltd. (“Haitong UniTrust” or the “Company” and its subsidiaries together, the “Group”; Stock Code:1905) is pleased to announce the…
Contracted Sales Rose to Exceed RMB 4,390 Million in 2019; Net Profit Increased by 54.6% to RMB 620 Million Huijing Holdings Company Limited (“Huijing Holdings” or the “Group”; Stock code:…
Group reported revenue up 1.5% year-on-year to HK$1,181.8 million; Group adjusted ebitda decreased 27.9% year-on-year to HK$87.0 million 2019 ANNUAL RESULTS HIGHLIGHTS Group Annual Results Achieved solid results with an…
Pillar Assets Grow Steadily, Financial Investments Stress on Resource Backflow Legend Holding Corporation (3396.HK) today announced its audited annual results for the 12 months ended December 31, 2019 (the “Reporting…
CStone Pharmaceuticals (“CStone”; Stock Code: 2616.HK), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and molecularly-targeted precision medicines for the treatment of cancer, today released…
Wintermar Offshore Marine (WINS:JK) has reported results for the 2019 financial year, with a smaller Net Loss of US$13.3 million for FY2019, a drop of 48% from the previous year,…
AIM ImmunoTech(NYSE-American交易代码: AIM)今天宣布，它正在积极寻找研究人员和地点进行安普利近的临床测试，测试其作为由SARS-CoV-2新型冠状病毒引发的新型肺炎的保护性预防和早期疗法的疗效。 该公司将临床试验目标选定在美国、欧洲、亚洲和阿根廷，并且作为临床试验开始前的必要步骤，目前公司正在征集一个或多个国家和地区的一个或多个地点以及符合资质的首席研究员。潜在临床试验的医疗方案已处于研发的最后阶段。接下来AIM打算寻求机构审查委员会的批准和政府授权，以尽快开始进行将安普利近作为保护性预防和早期疗法的临床试验。 在过去两个月中，AIM已达到几个重要的新冠肺炎里程碑： – 在寻求国内外研究合作伙伴之前，AIM提交了临时专利申请来保护公司的知识产权。 – 日本国立传染病研究所(NIID)同意将安普利近作为新冠肺炎的潜在治疗药物进行试验。测试和研究将在NIID和东京大学的实验室中进行。 AIM会在收到结果后立即报告。 – AIM与“中国走出去”网站(CGA)合作，以促进安普利近在中华人民共和国(PRC)的临床前及临床试验。 – AIM正在与阿根廷的GP-Pharm进行商谈，以推进安普利近对抗新冠肺炎的潜在用途。在阿根廷境内，安普利近是一种获准用于治疗肌痛性脑脊髓炎/慢性疲劳综合征的药物。 – AIM正在与myTomorrows和鹿特丹大学医学院(Erasmus MC)进行讨论——目前它们将安普利近用于胰腺癌患者的治疗，以探索对安普利近进行快速临床前和临床试验。 “自疫情爆发以来，我们一直致力于研发安普利近，期待其成为这种高致病性冠状病毒的鼻内和口服保护性预防药物以及静脉注射早期治疗药物。”AIM首席执行官Thomas K. Equels表示。 “世界各地站在抗击这一流行病前线的工作人员清楚，他们的家人也同样明白，他们每天都在冒着生命危险与新冠肺炎病人打交道。例如，在西班牙报告的病例中，医护人员感染比例高达13%。我的一个儿子和一个外甥是医生，一个女儿和一个妹妹在做护士，三个侄子是急救人员，还有一个侄子是警察。这场斗争对我而言是一场个人的战斗，全世界无数人也面临与我一样的境况。在缺乏有效疫苗的情况下，研发如安普利近之类的早期治疗药物，可能对一线工作人员的健康和遏制大流行的蔓延都意义非凡。” AIM还在继续等待六项正在进行的临床试验的结果，这些临床试验研究了安普利近对不同类型癌症的疗效，目前实验还在稳步推进中。随着更多关于这些研究的信息披露，公司也会及时将最新信息告知股东和市场。为此，该公司今天向罗斯威尔帕克综合癌症中心(Roswell Park Comprehensive Cancer Center)提交了一份《材料调拨和研究协议》的适时执行修正案，并附有一份展示正在进行或即将进行的临床试验的证明。癌症患者是新冠肺炎的易感人群。我们还认识到，与所有医疗机构一样，所有的癌症中心也都必须对这一流行病进行一级响应。因此，鉴于新冠肺炎的医疗应急状况，癌症患者正在进行的临床实验登记和报告可能会出现延迟。 关于AIM ImmunoTech公司 AIM ImmunoTech公司是一家免疫制药公司，专门从事治疗免疫疾病、病毒性疾病和多种癌症的疗法的研究和开发。AIM的主打产品包括阿根廷批准的药物rintatolimod(商品名安普利近®或Rintamod®)和FDA批准的药物Alferon…
